Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 3Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 681Neoplasms 593Carcinoma, Non-Small-Cell Lung 292Colorectal Neoplasms 291Prostatic Neoplasms 284Lung Neoplasms 224Melanoma 161Multiple Myeloma 151Neoplasm Metastasis 145Pancreatic Neoplasms 143Head and Neck Neoplasms 143Ovarian Neoplasms 136Carcinoma, Hepatocellular 126Leukemia, Myeloid, Acute 122Colonic Neoplasms 114Brain Neoplasms 113Squamous Cell Carcinoma of Head and Neck 111Uterine Cervical Neoplasms 109Stomach Neoplasms 104Lymphoma 101Recurrence 100Glioblastoma 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 83Lymphoma, Non-Hodgkin 82Urinary Bladder Neoplasms 78Lymphoma, Follicular 78Hematologic Neoplasms 78Glioma 75Parkinson Disease 4, Autosomal Dominant Lewy Body 73Sarcoma 72

Interventions

talimogene laherparepvec 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Ductal × 1 year × Clear all
NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
50 enrolled 12 charts
Breast

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡